Amylyx stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting

Amylyx Pharmaceuticals, Inc.

Elected George Mclean Milne Jr., Ph.D. (76.9M for, 14.1M withheld) and Paul Fonteyne (86.3M for, 4.8M withheld) as Class II directors.
Ratified Deloitte & Touche as independent auditor for FY 2026: 102.0M for, 34.5K against, 5.6K abstain.
Approved non-binding advisory vote on named executive officer compensation: 77.5M for, 13.5M against, 21.1K abstain.
No other matters were voted on at the June 4, 2026 Annual Meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.